These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9000132)
1. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Cortez D; Stoica G; Pierce JH; Pendergast AM Oncogene; 1996 Dec; 13(12):2589-94. PubMed ID: 9000132 [TBL] [Abstract][Full Text] [Related]
2. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Hoover RR; Gerlach MJ; Koh EY; Daley GQ Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388 [TBL] [Abstract][Full Text] [Related]
3. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Kurosu T; Ohki M; Wu N; Kagechika H; Miura O Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808 [TBL] [Abstract][Full Text] [Related]
4. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544 [TBL] [Abstract][Full Text] [Related]
5. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Laneuville P; Timm M; Hudson AT Cancer Res; 1994 Mar; 54(5):1360-6. PubMed ID: 8118826 [TBL] [Abstract][Full Text] [Related]
6. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378 [TBL] [Abstract][Full Text] [Related]
7. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Cambier N; Chopra R; Strasser A; Metcalf D; Elefanty AG Oncogene; 1998 Jan; 16(3):335-48. PubMed ID: 9467959 [TBL] [Abstract][Full Text] [Related]
8. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Cortez D; Kadlec L; Pendergast AM Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705 [TBL] [Abstract][Full Text] [Related]
9. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Dan S; Naito M; Tsuruo T Cell Death Differ; 1998 Aug; 5(8):710-5. PubMed ID: 10200527 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551 [TBL] [Abstract][Full Text] [Related]
11. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Wang Z; Sampath J; Fukuda S; Pelus LM Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298 [TBL] [Abstract][Full Text] [Related]
12. BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion. Jin A; Kurosu T; Tsuji K; Mizuchi D; Arai A; Fujita H; Hattori M; Minato N; Miura O Oncogene; 2006 Jul; 25(31):4332-40. PubMed ID: 16518411 [TBL] [Abstract][Full Text] [Related]
13. CML and apoptosis: the ceramide pathway. Maguer-Satta V Hematol Cell Ther; 1998 Oct; 40(5):233-6. PubMed ID: 9844818 [TBL] [Abstract][Full Text] [Related]
14. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571. Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533 [TBL] [Abstract][Full Text] [Related]
17. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Ren SY; Xue F; Feng J; Skorski T Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545 [TBL] [Abstract][Full Text] [Related]
18. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Gambacorti-Passerini C; le Coutre P; Mologni L; Fanelli M; Bertazzoli C; Marchesi E; Di Nicola M; Biondi A; Corneo GM; Belotti D; Pogliani E; Lydon NB Blood Cells Mol Dis; 1997 Dec; 23(3):380-94. PubMed ID: 9446752 [TBL] [Abstract][Full Text] [Related]
20. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line. Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]